245 related articles for article (PubMed ID: 34032157)
21. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.
Akce M; Chang E; Haeri M; Perez M; Finch CJ; Udden MM; Mims MP
Case Rep Hematol; 2016; 2016():3598547. PubMed ID: 27957358
[TBL] [Abstract][Full Text] [Related]
23. Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient.
Pokhrel A; Yuldasheva O; Mirashi E; Nair K; Salyana M; Jaswani V; Avezbakiyev B; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096211065633. PubMed ID: 35073776
[TBL] [Abstract][Full Text] [Related]
24. Plasmablastic lymphoma of the gastrointestinal tract: A rare entity with a dismal prognosis.
Komaranchath AS; Haleshappa RA; Kuntegowdenahalli LC; Kumar RV; Dasappa L; Babu G
Indian J Cancer; 2016; 53(4):529-533. PubMed ID: 28485344
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
26. [Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
Feng J; Xu L; Dong HJ; Zhang N; Bai QX; Liang R; Shu MM; Yang L; Chen XQ; Gu HT; Gao GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1350-1354. PubMed ID: 30295249
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
Front Immunol; 2021; 12():702593. PubMed ID: 34322131
[TBL] [Abstract][Full Text] [Related]
28. A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma.
Kessler AJ; Marcellino BK; Niglio SA; Petersen BE; Malone AK
Case Rep Hematol; 2019; 2019():2907317. PubMed ID: 30906602
[TBL] [Abstract][Full Text] [Related]
29. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
30. Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
Mota F; Mesquita B; Carvalho S; Coelho A; Velho G; Lima M; Selores M
Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617520
[TBL] [Abstract][Full Text] [Related]
31. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
32. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Jessa R; Chien N; Villa D; Freeman CL; Slack GW; Savage KJ; Scott DW; Sehn LH; Song KW; Gerrie AS
Br J Haematol; 2022 Oct; 199(2):230-238. PubMed ID: 35961783
[TBL] [Abstract][Full Text] [Related]
34. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
Castillo J; Pantanowitz L; Dezube BJ
Am J Hematol; 2008 Oct; 83(10):804-9. PubMed ID: 18756521
[TBL] [Abstract][Full Text] [Related]
35. Orbital plasmablastic lymphoma with remission following chemotherapy.
Degnan AJ; Levy LM
J Radiol Case Rep; 2011; 5(2):1-7. PubMed ID: 22470775
[TBL] [Abstract][Full Text] [Related]
36. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
37. Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.
Samoon Z; Idrees R; Masood N; Ansari TZ
BMC Res Notes; 2015 May; 8():180. PubMed ID: 25933603
[TBL] [Abstract][Full Text] [Related]
38. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.
Elyamany G; Al Mussaed E; Alzahrani AM
Adv Hematol; 2015; 2015():315289. PubMed ID: 26357515
[TBL] [Abstract][Full Text] [Related]
39. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.
Yamada T; Hara T; Goto N; Iwata H; Tsurumi H
Int J Hematol; 2019 Jun; 109(6):723-730. PubMed ID: 30859398
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous plasmablastic lymphoma.
Jambusaria A; Shafer D; Wu H; Al-Saleem T; Perlis C
J Am Acad Dermatol; 2008 Apr; 58(4):676-8. PubMed ID: 18342714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
